Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of kanser tiroid.
Eisai berkata Lenvima akan menjadi standard baharu untuk rawatan klinikal kanser tiroid yang tidak boleh dibuang. Industri ini sangat optimistik tentang Lenvima, dan dijangka ubat itu akan menjadi lembu tunai baharu untuk Eisai, dengan jualan tahunan memuncak pada lebih daripada $ 1 bilion.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved tumor volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
Pada masa ini, walaupun kebanyakan jenis kanser tiroid boleh dirawat, terdapat beberapa pilihan untuk rawatan apabila ia menjadi lebih teruk. Kanser tiroid pembezaan (DTC) adalah tumor tiroid malignan yang paling biasa, dan kejadiannya telah meningkat secara berterusan dalam beberapa tahun kebelakangan ini.
Lenvatinib ialah perencat tirosin kinase (RTK) multi-reseptor oral dengan mod pengikatan novel. Selain menghalang RTK lain yang terlibat dalam percambahan tumor dan laluan isyarat onkogenik, ia juga boleh secara selektif menghalang aktiviti kinase reseptor faktor pertumbuhan endothelial vaskular (VEGF).
